On August 31, 2026, Longevity Health Holdings, Inc. entered into a Securities Purchase Agreement with Puritan Partners LLC to issue and sell a 10% Senior Secured Convertible Note due February 29, 2028. The Company received $375,000 in proceeds from the sale of the Note, which has an original principal amount of $416,667 reflecting a 10% original issue discount. Interest accrues at 10% per annum and is payable monthly in cash. The Note is convertible into common stock at a fixed price of $0.50 per share or an alternative market-based price if the closing trading price falls below the conversion price, subject to beneficial ownership limitations. Proceeds are designated for working capital purposes. Longevity Health Holdings, Inc. operates in the longevity and regenerative medicine industry.

Longevity Health Holdings announced on August 17, 2026, that it settled litigation with Puritan Partners LLC to resolve disputes dating back to November 2023. Under the settlement terms, the company exchanged existing debt and warrants for new 10% senior secured convertible notes totaling $2,350,000 in aggregate principal amount, maturing in February 2028. This resolution removes a significant overhang that had previously constrained the company's access to capital and strategic opportunities. Longevity Health Holdings operates in the bio-aesthetics industry, developing and marketing cosmetic skincare and haircare products focused on human longevity and healthy aging.

Longevity Health Holdings, Inc. entered into a settlement agreement with Puritan Partners LLC on August 13, 2026, resolving litigation regarding a prior Securities Purchase Agreement and convertible note. The company issued two new 10% Senior Secured Convertible Notes maturing February 5, 2028: an Initial Note of $1,250,000 exchanged for the existing note and an Additional Note of $1,100,000 exchanged for a warrant. These notes are secured by a first-priority lien on substantially all assets and carry an initial conversion price of $0.50 per share. Additionally, director Scott Frisch resigned from the Board effective August 11, 2026, citing no disagreements with company operations. The company operates in the longevity health and regenerative medicine sector.